Danish pharmaceutical company Novo Nordisk is partnering with American artificial intelligence company Anthropic, aiming to use Anthropic’s Claude model to advance its drug discovery research and development.

Novo, the developer of the popular weight loss drug Ozempic, announced the partnership on Wednesday, saying it will help the company in its mission to become “the world’s most AI-driven healthcare company.” The Danish company added that it would use Anthropic’s leading frontier models to aid its own software development, with the announcement coming during a week of debate over frontier AI in the United States, with Anthropic at the helm of the discussions.

Recommended Stories

Bill Gates disagrees with AI leaders on self-regulation

Big Tech is predicting the apocalypse. The real AI threat is much bigger

Trump was right about the lab leak. He’s right about AI, too